Daily Adaptive Radiation Therapy for Prostate Cancer
This study is testing a new way to deliver radiation therapy called daily adaptive SBRT with urethral sparing (DEVICE) for men with low or intermediate risk prostate cancer. This treatment adjusts the radiation plan each day based on imaging to protect the urethra (the tube that carries urine out of the body). The main goal is to see if this approach reduces urinary side effects, which will be measured by a questionnaire 90 days after treatment ends. You might be able to join if you are a man aged 18 or older with biopsy-proven prostate cancer, a prostate size of 80cc or less, and a low urinary symptom score. The study plans to enroll 132 participants.
- Study design
- This is a single-arm, multi-center study, meaning all participants will receive the same treatment. It aims to enroll 132 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your urinary side effects will be assessed 90 days after the end of the SBRT treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer
At a glance
Conditions
Where it's being run
8 sites across 7 statesStudy leadership
- Jonathan Leeman, MD · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
- Jeremy Bredfeldt, PhD · PRINCIPAL_INVESTIGATOR · Brigham and Women's Hospital
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Patient-reported acute urinary toxicity90 days after end of SBRT
Minimum clinically important change (MCIC) status in patient-reported urinary QOL, as determined by the worst change reported by each subject in their EPIC-26 urinary domain scores.